Genfit S.A. (GNFTF)
USD 5.55
(0.0%)
USD 5.55
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 28.56 Million EUR | 32.16% |
| 2022 | 21.61 Million USD | -76.25% |
| 2021 | 91 Million USD | 9623.1% |
| 2020 | 936.01 Thousand USD | -97.86% |
| 2019 | 43.71 Million USD | 55317.58% |
| 2018 | 78.87 Thousand USD | -44.33% |
| 2017 | 141.69 Thousand USD | -52.7% |
| 2016 | 299.54 Thousand USD | -47.68% |
| 2015 | 572.48 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 FY | 28.56 Million EUR | 32.16% |
| 2023 Q2 | 11.48 Million USD | 40.09% |
| 2023 Q1 | 8.19 Million EUR | -32.85% |
| 2023 Q3 | 2.81 Million EUR | -75.46% |
| 2023 Q4 | 14.26 Million EUR | 406.21% |
| 2022 Q4 | 12.2 Million USD | 129.87% |
| 2022 Q3 | 5.31 Million EUR | -39.59% |
| 2022 Q2 | 8.79 Million USD | 0.0% |
| 2022 FY | 21.61 Million USD | -76.25% |
| 2021 Q2 | 13.04 Thousand USD | 0.0% |
| 2021 FY | 91 Million USD | 9623.1% |
| 2021 Q4 | 90.99 Million USD | 0.0% |
| 2020 Q2 | 137.02 Thousand USD | 0.0% |
| 2020 FY | 936.01 Thousand USD | -97.86% |
| 2020 Q4 | 786.74 Thousand USD | 0.0% |
| 2019 FY | 43.71 Million USD | 55317.58% |
| 2019 Q2 | 1138.80 USD | 0.0% |
| 2019 Q4 | 34.61 Million USD | 0.0% |
| 2018 FY | 78.87 Thousand USD | -44.33% |
| 2017 FY | 141.69 Thousand USD | -52.7% |
| 2016 FY | 299.54 Thousand USD | -47.68% |
| 2015 FY | 572.48 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -81.101% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -162007.712% |
| SQZ Biotechnologies Company | 21.47 Million USD | -32.997% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -56.795% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | 76.768% |
| Mesoblast Limited | 5.9 Million USD | -383.988% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Genus plc | 668.8 Million USD | 95.729% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -6864.27% |
| Marizyme, Inc. | 645.81 Thousand USD | -4323.128% |
| ContraFect Corporation | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -37112.908% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -43359.408% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -72183.516% |
| MultiCell Technologies, Inc. | 49.32 USD | -57917580.454% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | 42.549% |
| EV Biologics, Inc. | 48.9 Thousand USD | -58315.133% |
| Q BioMed Inc. | 284.35 Thousand USD | -9945.648% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | 3.487% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | 88.356% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -40707.143% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -28755.284% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -37622.519% |
| IMV Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -4237.889% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 99.806% |
| Halberd Corporation | 999.00 USD | -2859259.359% |
| Enzolytics Inc. | 52.79 Thousand USD | -54004.478% |
| Resverlogix Corp. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -1986.56% |
| SYBLEU INC | 11.69 Thousand USD | -244128.796% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -4594.137% |
| argenx SE | 1.22 Billion USD | 97.671% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -1378.52% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -4526.78% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 839.52 Million USD | 96.597% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | 80.314% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -5021.838% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -2763.01% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | 40.925% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 16.68 Million USD | -71.198% |
| ONE Bio Corp. | 52.29 Million USD | 45.378% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Agentix Corp. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -11975.161% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -11975.161% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -20268.363% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -5929.806% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -266.735% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -219630.769% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -72154.262% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -757.808% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -328.582% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -2649.278% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -10.859% |
| CSL Limited | 14.8 Billion USD | 99.807% |
| Cellectis S.A. | 755 Thousand USD | -3683.444% |